Frekil blog · Jun 2026
Technical post on empirical calibration and statistical rigor in observational data analysis.
Intelligence Layer for Real World Clinical Data
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Frekil is a YC-backed healthcare AI company building real-world evidence (RWE) infrastructure that turns clinical data into publication-ready evidence in minutes. Public sources also show an earlier launch narrative around medical imaging annotation, but the current official positioning is RWE automation for pharma, biotech, and CRO workflows.
Primary product
AI-powered real-world evidence infrastructure / end-to-end RWE study automation platform
Founded
2025
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Software Development
Sub-industry
Real-world evidence software
Offices
0 jobs at Frekil
Check back later for new openings
Business model
Stage
Seed
Total raised
$500K
Latest round
Seed · Apr 2025
Latest amount
$500K
Apr 2025
Investors
The company emphasizes radical transparency, scientific rigor, bias for action, direct access to the founders, and a strong security posture: no clinical data touches AI.
Pricing
Flexible enterprise pricing with per-study and platform options
Differentiators
Technology
Customers
Competitors
Estimated revenue
≈$330K ARR (GetLatka estimate)
Frekil blog · Jun 2026
Technical post on empirical calibration and statistical rigor in observational data analysis.
Frekil blog · May 2026
Describes Frekil's inspectable, multi-agent approach to RWE and why generic chatbots are insufficient for high-stakes evidence workflows.
Frekil blog · Apr 2026
Explains external control arms and why real-world evidence matters in clinical development.
Fondo · Feb 2026
Launch write-up describing Frekil's earlier medical-imaging annotation platform, 10x faster AI-assisted workflows, and certified radiologist marketplace.
Startup Intros · Apr 2025
Seed round announcement for Frekil; says the company raised $500K and names Y Combinator and 7BC Venture Capital as investors.